Nadilaz (Azelastine Hydrochloride, Fluticasone Propionate)

Azelastine hydrochloride is an H1‑receptor antagonist that blocks the action of histamine, a key mediator of allergic symptoms. In addition to antihistamine activity, it possesses anti‑inflammatory properties that reduce nasal mucosal edema and the release of inflammatory mediators.

The dosing regimen for Nadilaz is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. The prescriber will provide specific instructions on the number of sprays per nostril and the frequency of administration.

Safety data for Nadilaz in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To request Nadilaz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nadilaz combines an antihistamine (azelastine) with a corticosteroid (fluticasone) in a single spray, offering both rapid symptom relief and long‑term anti‑inflammatory control. Compared with single‑agent antihistamine sprays, it may provide superior reduction of nasal congestion, while offering a more convenient option than using separate antihistamine and steroid products.

Store Nadilaz at room temperature, preferably below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product after the expiration date printed on the label.

Nadilaz is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator to deliver the prescribed number of sprays. The process is then repeated in the other nostril if directed by the prescriber.

Serious adverse events, although rare, can include nasal septal perforation, severe or prolonged nosebleeds, adrenal suppression with prolonged high‑dose use, hypersensitivity reactions such as angioedema, opportunistic fungal infections of the nasal passages, and visual disturbances. Patients should seek medical attention if any of these occur.

Nadilaz should be avoided in individuals with known hypersensitivity to azelastine, fluticasone, or any of the excipients in the formulation. It is also contraindicated in patients who have had recent nasal surgery until the site has healed, and in those for whom systemic corticosteroid therapy is contraindicated.